Andrea M Malone, Lorna Storey, Michael McDermot and Owen P Smith
Anaplastic large cell lymphoma (ALCL) is an uncommon form of non-Hodgkin lymphoma in younger patients, accounting for less than 15% of cases. It is exceedingly rare in infants, with a median age at diagnosis of 12 years. Various treatment strategies have been studied in pediatric ALCL, however the long-term event free survival is approximately 70% regardless of treatment approach. We present the case of six month old infant with anaplastic lymphoma kinase (ALK) positive ALCL with unfavourable prognostic features. We elected to treat with upfront brentuximab in addition to combination chemotherapy. This achieved a clinical and molelcular remission of the disease. The treament was well tolerated.
Teile diesen Artikel
English 
Spanish 
Chinese 
Russian 
French 
Japanese 
Portuguese 
Hindi 